Atea Pharmaceuticals Inc (AVIR) Stock Price, Quote & News

Company Profile

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 284 8891

Website: ateapharma.com

Address:

225 Franklin Street, Suite 2100, Boston, United States

OnlyFibs Mar. 14 at 8:38 PM

$AVIR $AVIR 🧬 +40% this month — here's why Evercore PT raised $6 → $10 on Mar 9 Earnings call flagged 'pivotal 2026' Phase 2: 98% SVR12 cure rate for HCV C-BEYOND Phase 3 fully enrolled TOPLINE DATA DUE MID-2026 ← the event $301.8M cash — fully funded chart: $1.43 base → $6.45 parabolic now cooling — $5.38 is the key support hold $5.38 = bounce thesis intact break $4.14 = thesis off ⚠️ binary risk: data hits = $10+ data misses = gap to cash value high risk. high reward. know your size. #AVIR #Biotech #hovdid

0 · Reply

OnlyFibs Mar. 14 at 8:17 PM

$AVIR up 50% on this call..

0 · Reply

Cutlass Mar. 13 at 7:25 PM

$AVIR Strong week ✍️

0 · Reply

erevnon Mar. 9 at 6:54 PM

Evercore ISI Group maintains Atea Pharmaceuticals $AVIR at Outperform and raises the price target from $6 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Following_the_trend Mar. 9 at 3:22 PM

$AVIR Still moving up......

0 · Reply

VintageVibes Mar. 9 at 5:27 AM

$AVIR HCV Phase 3 (C-BEYOND): Enrollment of over 880 patients in North America is complete. Topline results are expected in mid-2026.

0 · Reply

FATSTAX Mar. 7 at 7:38 PM

$SPY $AVIR Short somethting else.

0 · Reply

StockScanners Mar. 7 at 4:04 AM

$AVIR keep watch if this holds above 5.48

0 · Reply

Barkingdogs Mar. 6 at 11:01 PM

$AVIR hep c is the ticket!!!

0 · Reply

Barkingdogs Mar. 6 at 10:59 PM

$AVIR Current Focus: The company is focused on its Phase 3 hepatitis C (HCV) program and has initiated a $25 million stock buyback program, signaling confidence in its independent path

0 · Reply

Top 2 Health Care Stocks That May Fall Off A Cliff This Month

ACLX

Mar 5, 2026, 6:55 PM EST - 16 days ago

Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call Transcript

Mar 5, 2026, 4:05 PM EST - 16 days ago

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 26, 2026, 7:00 AM EST - 23 days ago

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026

Feb 24, 2026, 7:00 AM EST - 25 days ago

Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026

Jan 15, 2026, 1:55 PM EST - 2 months ago

Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 8, 2026, 7:00 AM EST - 2 months ago

Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:00 AM EST - 2 months ago

Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 23, 2025, 5:51 AM EST - 3 months ago

Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026

Dec 22, 2025, 7:00 AM EST - 3 months ago

Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Nov 19, 2025, 7:00 AM EST - 4 months ago

Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference

Nov 13, 2025, 2:31 PM EST - 4 months ago

Atea Pharmaceuticals, Inc. (AVIR) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements Transcript

Nov 12, 2025, 7:01 PM EST - 4 months ago

Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 4:05 PM EST - 4 months ago

Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 7, 2025, 8:00 AM EST - 4 months ago

Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

Nov 5, 2025, 7:00 AM EST - 4 months ago

Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025

Oct 22, 2025, 7:00 AM EDT - 5 months ago

Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025

Oct 7, 2025, 8:00 AM EDT - 5 months ago

Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

Sep 9, 2025, 5:51 PM EDT - 6 months ago

Atea Pharmaceuticals, Inc. (AVIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 2, 2025, 7:00 AM EDT - 7 months ago

Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 8, 2025, 3:29 PM EDT - 8 months ago

Atea Pharmaceuticals, Inc. (AVIR) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 8 months ago

Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 7:00 AM EDT - 8 months ago

Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025

Jun 24, 2025, 7:00 AM EDT - 9 months ago

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

May 12, 2025, 4:11 PM EDT - 11 months ago

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 7:00 AM EDT - 11 months ago

Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025

May 1, 2025, 7:00 AM EDT - 11 months ago

Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025

Apr 23, 2025, 7:00 AM EDT - 11 months ago

Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025

Apr 17, 2025, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

Apr 9, 2025, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Mar 31, 2025, 7:04 PM EDT - 1 year ago

Driver Notifies Atea Pharmaceuticals of Withdrawal of Notice of Nomination

Mar 26, 2025, 1:58 PM EDT - 1 year ago

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

Mar 26, 2025, 8:00 AM EDT - 1 year ago

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Mar 21, 2025, 5:54 PM EDT - 1 year ago

Atea Pharmaceuticals Issues Statement Regarding Director Nominations

Mar 19, 2025, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025

Mar 6, 2025, 6:14 PM EST - 1 year ago

Atea Pharmaceuticals, Inc. (AVIR) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 4:05 PM EST - 1 year ago

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025

Feb 24, 2025, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

Jan 8, 2025, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 5:05 PM EST - 1 year ago

Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process

Dec 16, 2024, 5:00 AM EST - 1 year ago

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

Dec 4, 2024, 3:14 PM EST - 1 year ago

After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study

Dec 4, 2024, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)

Nov 26, 2024, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference

Nov 15, 2024, 11:00 AM EST - 1 year ago

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024

Nov 9, 2024, 1:14 PM EST - 1 year ago

Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:05 PM EST - 1 year ago

Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19

OnlyFibs Mar. 14 at 8:38 PM

0 · Reply

OnlyFibs Mar. 14 at 8:17 PM

$AVIR up 50% on this call..

0 · Reply

Cutlass Mar. 13 at 7:25 PM

$AVIR Strong week ✍️

0 · Reply

erevnon Mar. 9 at 6:54 PM

Evercore ISI Group maintains Atea Pharmaceuticals $AVIR at Outperform and raises the price target from $6 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Following_the_trend Mar. 9 at 3:22 PM

$AVIR Still moving up......

0 · Reply

VintageVibes Mar. 9 at 5:27 AM

$AVIR HCV Phase 3 (C-BEYOND): Enrollment of over 880 patients in North America is complete. Topline results are expected in mid-2026.

0 · Reply

FATSTAX Mar. 7 at 7:38 PM

$SPY $AVIR Short somethting else.

0 · Reply

StockScanners Mar. 7 at 4:04 AM

$AVIR keep watch if this holds above 5.48

0 · Reply

Barkingdogs Mar. 6 at 11:01 PM

$AVIR hep c is the ticket!!!

0 · Reply

Barkingdogs Mar. 6 at 10:59 PM

$AVIR Current Focus: The company is focused on its Phase 3 hepatitis C (HCV) program and has initiated a $25 million stock buyback program, signaling confidence in its independent path

0 · Reply

Barkingdogs Mar. 6 at 10:58 PM

$AVIR is not currently in a finalized buyout deal. While the company previously rejected an unsolicited $5.75 per share offer from Concentra Biosciences in May 2023, the company later engaged in exploring strategic alternatives, including potential partnerships or mergers, to maximize shareholder value. Strategic Review: As of early 2025, Atea was exploring strategic alternatives to maximize value, though no specific, accepted acquisition deal has been announced. Current Focus: The company is focused on its Phase 3 hepatitis C (HCV) program and has initiated a $25 million stock buyback program, signaling confidence in its independent path. Performance: Despite previous takeover interest, the company has recently shown positive stock momentum, trading near 52-week highs in early 2026.

0 · Reply

Barkingdogs Mar. 6 at 10:58 PM

$AVIR The global Hepatitis C (HCV) market is experiencing significant growth, valued between USD 17 billion and USD 75 billion in 2024-2025, with projections to reach over USD 197 billion by 2032–2034. Driven by high-efficiency, direct-acting antiviral (DAA) therapies and increased diagnosis rates, the market is expanding at a CAGR of 9% to 14%. BioSpaceBioSpace +4 Key details regarding the Hep C market size: Market Value (2024-2025): Estimates vary, with Market.us reporting USD 71.2 billion in 2024 and Yahoo Finance reporting USD 17.02 billion in the same year, highlighting differences in scope. Growth Projections: The market is expected to grow rapidly, with forecasts reaching USD 197.24 billion by 2032 (Data Bridge Market Research) or USD 243.8 billion by 2034 (Market.us).

0 · Reply

Barkingdogs Mar. 6 at 10:23 PM

$AVIR ) is not currently in a finalized buyout deal. While the company previously rejected an unsolicited $5.75 per share offer from Concentra Biosciences in May 2023, the company later engaged in exploring strategic alternatives, including potential partnerships or mergers, to maximize shareholder value.

0 · Reply

Cutlass Mar. 6 at 7:58 PM

$AVIR I don't think we will see the golden two's again ☹️

1 · Reply

Cutlass Mar. 6 at 3:25 PM

$AVIR Buyers stepping in again - 👀

0 · Reply

Following_the_trend Mar. 6 at 3:02 PM

$AVIR Strong!

0 · Reply

Chrissytina Mar. 6 at 1:59 PM

$AVIR This has had a nice run up for the past month plus all the sudden some post on this board all before earnings, now nothing but a dump this morning with no post 🤦🏼‍♀️ also down $.65 cents all ready! Looks like a pump & dump 😡

1 · Reply

StocktwitsEarnings Mar. 5 at 10:15 PM

$AVIR Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.57 down -42.50% YoY • Atea Pharmaceuticals Inc expects to submit an NDA for its HCV regimen in March 2027 and initiate a Phase 1 study for AT-587 in mid-2026. The company anticipates incurring operating losses in 2026 and the foreseeable future, despite expected cost savings from a Q1 2025 workforce reduction.

0 · Reply

Cutlass Mar. 5 at 8:50 PM

$AVIR ER on deck - let's see what has been developing at Atea ✍️

1 · Reply

Cutlass Mar. 5 at 8:49 PM

$AVIR The combination regimen of bemnifosbuvir and ruzasvir is in a global Phase 3 development program. This regimen has the potential to offer a differentiated treatment option with low risk of drug-drug interactions, short treatment duration, and convenience with no food effect for HCV-infected patients with or without compensated cirrhosis.

0 · Reply

Social_Idiot Mar. 5 at 7:47 PM

$AVIR My AI alerted me to this. The chart looks absolutely beautiful but looking at the pipeline, I have questions. What's the relavance HCV when it can be already be cured (95% rate)?

0 · Reply

Gemola Mar. 5 at 6:40 PM

$AVIR AVIR earnings today Mar. 5th 2026

0 · Reply

Market Cap	450.94M
Revenue (ttm)	0.00
Net Income (ttm)	-158.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	950,100
Avg Vol	581,696
Day's Range	N/A - N/A
Shares Out	79.67M
Stochastic %K	2%
Beta	0.21
Analysts	Sell
Price Target	$8.00